Related references
Note: Only part of the references are listed.Long-term use of burosumab for the treatment of tumor-induced osteomalacia
C. Crotti et al.
OSTEOPOROSIS INTERNATIONAL (2023)
Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia
Yasuo Imanishi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2021)
Tumor induced osteomalacia: A single center experience on 17 patients
C. Crotti et al.
BONE (2021)
Burosumab for the Treatment of Tumor-Induced Osteomalacia
Suzanne M. Jan de Beur et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2021)
FGF23 Neutralizing Antibody Partially Improves Bone Mineralization Defect of HMWFGF2 Isoforms in Transgenic Female Mice
Liping Xiao et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study (vol 12, e0175207, 2017)
Robert J. Moots et al.
PLOS ONE (2017)
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Vibeke Strand et al.
BIODRUGS (2017)
Tumor induced osteomalacia: associated with elevated circulating levels of fibroblast growth factor-7 in addition to fibroblast growth factor-23
Shweta Bansal et al.
CLINICAL NEPHROLOGY (2016)
Tumor-induced osteomalacia with normal systemic fibroblast growth factor-23 level
Ambika Amblee et al.
CLINICAL KIDNEY JOURNAL (2014)
Expression of dentin matrix protein 1 in tumors causing oncogenic osteomalacia
S Toyosawa et al.
MODERN PATHOLOGY (2004)
MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia
PSN Rowe et al.
GENOMICS (2000)